Lumexa Imaging Holdings, Inc. (LMRI)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$12.18+2.35%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Lumexa Imaging aims for revenue near $1.07 billion in 2026. Profit targets are $234 to $242 million in adjusted EBITDA. The company grows by partnering with hospitals and expanding imaging centers. Earnings per share are expected around $0.74 in 2026.
The company has missed earnings recently and faces elevated risks. New financial obligations may pressure cash flow. If revenue or profit targets slip, growth could stall.
The stock price is about 55% below our valuation level near $27. The market may be cautious due to recent earnings misses and financial risks, while our view expects the company to meet its revenue and profit goals.
Breaks if: Adjusted EBITDA falls below $234 million in 2026
Maintain Adjusted EBITDA within the range of $234 million to $242 million for full year 2026.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a cyclical play within the healthcare sector, which is currently experiencing a tailwind. The thesis is in a state of development, with recent earnings showing promise but also a history of misses that raises caution.
The market appears to have a low expectations gap, suggesting that current valuations reflect a justified outlook. There is a low level of fragility in the stock, indicating that the market does not expect significant volatility in the near term.
Management is on track to meet its revenue and Adjusted EBITDA targets for 2026, which supports a positive fundamental outlook. However, there is a near-term risk of missing earnings expectations, as the company has a recent history of consecutive misses.
The future performance of LMRI hinges on the company's ability to maintain its revenue guidance and the broader healthcare sector's performance, particularly if major players continue to exceed earnings expectations. Additionally, any cuts to guidance or worsening economic indicators could negatively impact sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook for LMRI. Record advanced modality volume is expected to increase outpatient imaging growth. The joint venture expansion aims to achieve $234 to $242 million in adjusted EBITDA for 2026.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. Adjusted EBITDA increased from $51.2 million in 2026-Q1 to $56.4 million in 2026-Q2. Management narrowed full-year 2026 Adjusted EBITDA guidance to $235 million to $241 million, reaffirming the target and showing progress consistent with expectations.
“Narrowing its full-year 2026 Adjusted EBITDA guidance range to $235 million to $241 million.”
“Lumexa Imaging continues to expect Adjusted EBITDA of $234 to $242 million.”
Breaks if: EPS falls below $0.71 per share in 2026
Breaks if: No new partnerships or JV expansions announced in 2026
Breaks if: Annual revenue falls below $1.045 billion in 2026
Continue to grow consolidated revenues to between $1.045 billion and $1.097 billion for full year 2026.
Stated as a priority in 2 of last 2 quarters. Consolidated revenues increased from $252.5 million in 2026-Q1 to $264.2 million in 2026-Q2, a 4.6% growth. Management reiterated full-year 2026 revenue guidance of $1.045 billion to $1.097 billion in both quarters, indicating consistent delivery and reaffirmation of this growth target.
“Reiterating full-year 2026 consolidated revenue guidance of $1.045 billion to $1.097 billion.”
“Lumexa Imaging continues to expect consolidated revenues of $1.045 to $1.097 billion.”
Over the next 1 to 3 years, LMRI's performance will depend on management's execution and external market conditions. Not investment advice.